To do so, we used specific chemical inhibitors and activators that target p38, JNK, MK2, c-Jun, Akt or Erk, which we applied during distinct phases of the infection (i.e., early or late) to assess their impact on viral growth. This evidence concerns the gene MAPK8 and infection.